Santen Pharmaceutical Co., Ltd. Investors Stock Price Information IR News News list Nov 18, 2021 Santen and ActualEyes sign a joint development agreement on Phase II clinical trial (Phase II a / PoC study) for a treatment candidate for Fuchs endothelial corneal dystrophy Nov 18, 2021 Santen and Ube Industries receives Complete Response Letter from FDA for STN1011700/DE-117 Nov 12, 2021 Santen to Present Latest Data on Omidenepag Isopropyl at AAO 2021 Management Policies CEO Message CORE PRINCIPLE / WORLD VISION Santen 2030 Medium Term Management Plan Corporate Governance Disclosure Policy Forward-Looking Statement Financial Summary Financial Highlights Financial Data Latest IR Documents Latest IR Documents IR Library Consolidated Performance Presentation Materials · videos Integrated Report (Annual Report) Data Book Pipeline Materials for the General Meeting of Shareholders Other IR Information IR Calendar Analyst Coverage Sustainability Library Stock Information Stock Basic Information Distribution of Profits to Shareholders and Dividends Stock Charts Overview Overview History Corporate Executives Organization Chart Global Operations IR Contact Investors Management Policies Financial Summary Latest IR Documents IR Library Other IR Information Stock Information Overview IR Contact play Contact Santen Pharmaceutical welcomes your inquiries and opinions. Sitemap Terms of Use Privacy Policy Copyright © 2017 Santen Pharmaceutical Co., Ltd. All Rights Reserved.